◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › 0-9 › 3347

Hangzhou Tigermed Consulting Co., Ltd (3347) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Diagnostics & Research · DATA UPDATED 2026-09-30

Hangzhou Tigermed Consulting Co., Ltd (3347) operates in the Diagnostics & Research industry and is headquartered in Hangzhou, China with about 11,984 employees. Its market capitalization is roughly HK$40 billion. In the fiscal year ended 2025-12-31, 3347 reported CNY 6.8B in revenue and CNY 888M in net income.

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally.

Interactive charts & full statements → Open the 3347 valuation workbench →

3347 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 6.8B	CNY 6.6B	CNY 7.4B	CNY 7.1B
Gross Profit	CNY 1.9B	CNY 2.2B	CNY 2.8B	CNY 2.8B
Operating Income (EBIT)	CNY 667M	CNY 1.1B	CNY 1.8B	CNY 1.8B
Net Income	CNY 888M	CNY 405M	CNY 2.0B	CNY 2.0B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3347 Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Total Revenue	CNY 1.9B	CNY 1.8B	CNY 1.8B	CNY 1.7B	CNY 1.6B
Gross Profit	CNY 541M	CNY 480M	CNY 408M	CNY 508M	CNY 470M
Operating Income (EBIT)	CNY 228M	CNY 200M	CNY 98M	CNY 206M	CNY 187M
Net Income	(CNY 462M)	CNY 49M	(CNY 132M)	CNY 218M	CNY 166M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3347 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CNY 344M)	(CNY 642M)	(CNY 590M)	(CNY 492M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3347 Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Dividends Paid	(CNY 24M)	(CNY 15M)	(CNY 3M)	(CNY 244M)	(CNY 27M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3347 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Assets	CNY 28.4B	CNY 28.7B	CNY 29.7B	CNY 27.4B
Total Liabilities	CNY 4.1B	CNY 4.6B	CNY 5.2B	CNY 4.8B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3347 viewer.

Other Companies in Diagnostics & Research

METROPOLIS · Metropolis Healthcare Limited — ₹112 billion
2268 · WuXi XDC Cayman Inc. — HK$102 billion
THYROCARE · Thyrocare Technologies Limited — ₹85 billion
2395 · Shin Nippon Biomedical Laboratories, Ltd. — JPY 56 billion
LONN · Lonza Group AG — CHF 40 billion
4671 · FALCO HOLDINGS Co., Ltd. — JPY 26 billion
VIMTALABS · Vimta Labs Limited — ₹26 billion
6127 · Joinn Laboratories(China)Co.,Ltd. — HK$23 billion

← 3339 All “0-9” companies 3348 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.